Nasdaq
$49.35▼ 0.08%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $4.76BShares out 96.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
19- 3d agoAfter-hours26.10.22 06:414Ownership#●●●
CRISPR Therapeutics AG
Insider Andrew Jacob Silver of CRISPR Therapeutics AG reported a change in beneficial ownership of securities as of October 19, 2026. This filing is a standard Form 4 disclosure regarding insider stock transactions.…more
$49.35-0.08%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 3d agoAfter-hours26.10.22 06:353Ownership
CRISPR Therapeutics AG
Andrew Jacob Silver, an officer of CRISPR Therapeutics AG, has filed a Power of Attorney for SEC reporting purposes. This document authorizes designated attorneys-in-fact to execute and file Forms 3, 4, and 5 on his behalf in compliance with Section 16(a) of the Securities Exchange Act of 1934.…more
$49.35-0.08%vs prev closeView filingShare - 4d agoAfter-hours26.10.21 06:354Ownership
CRISPR Therapeutics AG
Executive Samarth Kulkarni of CRISPR Therapeutics AG reported a change in beneficial ownership of company securities as of October 16, 2026. This filing serves as an official notification to the SEC regarding the insider's equity transaction.…more
$49.35-0.08%vs prev closeView filingShare
18 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoAfter-hours26.10.20 05:05#●●●
CRISPR Therapeutics Announces CFO Transition
CRISPR Therapeutics has appointed A.J. Silver as its new Chief Financial Officer, succeeding outgoing CFO Raju Prasad. The leadership transition is effective immediately as the company continues its financial operations.…more
$49.35-0.08%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.8Pre-market26.10.08 21:30
●●●●●●●● ●●●●● ●●●●●●
CRISPR Therapeutics will present Phase 1b clinical data for its cardiovascular gene editing candidate CTX310 at the American Heart Association Scientific Sessions 2026. The results are scheduled for a late-breaking oral presentation, with data remaining under embargo until the event.…more
$49.35-0.08%vs prev close - 10.2Regular26.10.02 23:15
●●●●●●●● ●●●●● ●●●●●●
CRISPR Therapeutics will present Phase 1 clinical data for its autoimmune disease candidate, zugo-cel, at the American College of Rheumatology Convergence 2026. This presentation provides an update on the company's ongoing research efforts in gene-edited therapies.…more
$49.35-0.08%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report